What is male breast cancer?
Male breast cancer is a malignant tumour that starts in the small amount of breast tissue every man has behind the nipple and areola. Most people think of breast cancer as a disease of women, but men have breast ducts too, and those ducts can turn cancerous in the same way.
The disease is rare. Fewer than 1 in 100 breast cancers occur in men. Because few men know it can happen to them, a lump under the nipple is often ignored or put down to harmless breast enlargement, and the cancer tends to be found later than in women.
Almost all breast cancers in men are fuelled by hormones: they carry receptors for oestrogen and grow in response to it. This is why hormone-blocking treatment, above all tamoxifen, plays a central role in treatment.
When it is found early, male breast cancer has a very good outlook. Most men are treated with surgery, often followed by hormone therapy and, depending on the tumour, radiotherapy, chemotherapy or targeted drugs.
1. Epidemiology
The American Cancer Society (ACS) estimates that in 2026 about 2,670 men in the United States will be diagnosed with invasive breast cancer and about 530 men will die from it. This compares with several hundred thousand breast cancer diagnoses in women each year.
The average lifetime risk for a man is about 1 in 755. In Western countries the yearly rate is roughly 1 new case per 100,000 men, and it has risen slowly over recent decades.
Key points
- Age: The risk rises steadily with age. The average age at diagnosis is between 60 and 70 years, somewhat older than in women. Men of any adult age can be affected, and cancers in younger men are more often linked to inherited gene changes.
- Ethnicity: In the United States, Black men are diagnosed more often than White men and tend to have less favourable outcomes, a pattern also seen in women.
- Stage at diagnosis: Men are more likely than women to be diagnosed at a later stage, mainly because there is no routine screening for men and symptoms are often overlooked.
2. Causes and How the Disease Develops
2.1 The male breast
Before puberty, boys and girls have similar breast tissue: a few ducts under the nipple surrounded by fat and connective tissue. In girls, oestrogen makes the tissue grow and develop milk-producing lobules. In boys, testosterone keeps it small. An adult man’s breast therefore contains mostly ducts and very few lobules.
This explains the types of cancer seen in men. Most are invasive ductal carcinomas (also called invasive carcinoma of no special type), which start in the ducts. Lobular carcinoma, common in women, is very rare in men.
2.2 The role of hormones
The balance between oestrogen and androgens (male hormones such as testosterone) is the main driver of male breast cancer. Oestrogen stimulates breast cells to divide. Anything that raises oestrogen, or lowers the effect of testosterone, increases risk:
| Cause of higher oestrogen | How it works |
|---|---|
| Obesity | Fat tissue converts androgens into oestrogen (aromatase). |
| Liver cirrhosis | The liver clears oestrogen less well. |
| Testicular problems | Undescended testes, mumps orchitis, injury or removal lower testosterone. |
| Klinefelter syndrome | 47,XXY: small testes, low testosterone, relatively high oestrogen. |
| Oestrogen treatment | E.g. older prostate cancer therapy or gender-affirming hormones. |
2.3 Inherited gene changes
A man’s risk is higher if blood relatives, women or men, have had breast cancer. Several inherited gene changes are known to raise the risk:
- BRCA2: The most important genetic risk factor. In a large analysis of carrier families, men with a harmful BRCA2 variant had an estimated 6.8% risk of breast cancer by age 70, compared with about 0.1% in men in general.
- BRCA1: Raises the risk less, to an estimated 1.2% by age 70.
- CHEK2 and PALB2: Variants in these genes give a moderate increase in risk.
- Other genes: PTEN (Cowden syndrome), TP53 (Li-Fraumeni syndrome) and the mismatch repair genes of Lynch syndrome have also been linked to male breast cancer.
Because inherited variants are relatively common in men with breast cancer and matter for treatment and for relatives, the American Society of Clinical Oncology (ASCO) recommends that all men with breast cancer be offered genetic counselling and germline genetic testing.
2.4 How the cancer develops
As in women, the cancer is thought to develop in steps. Normal duct cells first become overactive (hyperplasia), then may turn into ductal carcinoma in situ (DCIS), where cancer cells are still confined inside the ducts. Finally, the cells break through the duct wall and become invasive.
Pure DCIS is less common in men than in women, largely because it is usually found by screening mammograms, which men do not have.
3. Risk Factors
Many men who develop breast cancer have no known risk factor apart from age. The main known factors are summarised below.
| Risk factor | Effect on risk |
|---|---|
| Older age | Risk rises steadily; most cases occur after 60 |
| Family history of breast or ovarian cancer (especially in a male relative), or of prostate or pancreatic cancer | Increased; may point to an inherited gene change |
| BRCA2 variant | Strongly increased (about 7% by age 70) |
| BRCA1, CHEK2, PALB2 variants | Moderately increased |
| Klinefelter syndrome | Strongly increased; in a large British cohort, deaths from breast cancer were more than 50 times higher than expected |
| Radiation to the chest (for example for lymphoma in youth) | Increased, usually many years later |
| Liver cirrhosis | Increased through higher oestrogen levels |
| Testicular conditions | Increased through lower testosterone |
| Oestrogen treatment | Increased |
| Obesity | Increased through conversion of androgens to oestrogen in fat tissue |
| Heavy alcohol use | Increased, partly through liver damage |
Gynaecomastia, the common benign enlargement of male breast tissue, is not a precancerous condition. It can, however, share causes with breast cancer (such as hormonal imbalance), and it can hide a lump.
4. How does it look?
Unlike women, men are not offered screening mammograms, so male breast cancer is nearly always found because the man, his partner or a doctor notices a change in the chest.
Because the breast tissue in men lies mainly under the nipple, the cancer usually appears there.
4.1 The lump
| Feature | Typical finding |
|---|---|
| Location | Usually just under or beside the nipple (retroareolar). |
| Feel | Hard or firm, often irregular. |
| Pain | Usually painless. |
| Mobility | May move at first; later fixed to skin or muscle. |
| Side | Almost always one side only. |
4.2 Changes in the nipple
Because the tumour is so close to the nipple, nipple changes are common in men:
- Retraction: The nipple is pulled inwards or flattened. A nipple that newly turns in is an important warning sign.
- Discharge: Fluid coming from one nipple without squeezing, especially if it is bloody.
- Sores or crusting: A scaly, red or crusted nipple, or an open sore, can be a sign of cancer, including Paget disease of the nipple.
4.3 Changes in the skin
- Dimpling or puckering: The skin over the lump may be pulled inwards.
- Peau d’orange: In more advanced cases, swelling of the skin gives it a pitted look like orange peel.
- Redness and swelling: May be seen when the cancer has spread into the skin.
- Ulceration: An open wound over the lump is a sign of locally advanced disease.
4.4 Lumps in the armpit
Enlarged, firm lymph nodes in the armpit on the same side may be felt. This often means the cancer has spread to the lymph nodes, and sometimes an armpit lump is the first thing a man notices.
4.5 Cancer or gynaecomastia?
Gynaecomastia is far more common than breast cancer. The table shows typical differences, but only an examination and tests can tell them apart with certainty.
| Feature | Gynaecomastia | Breast cancer |
|---|---|---|
| Feel | Soft to rubbery, disc-shaped, centred under the nipple | Hard, often irregular, may be off-centre |
| Sides | Often both | Almost always one |
| Tenderness | Often tender, especially when new | Usually painless |
| Nipple | Normal | May be pulled in, bleed or crust |
| Skin | Normal | May dimple, redden or ulcerate |
| Armpit nodes | Normal | May be enlarged |
5. Symptoms
Early male breast cancer usually causes few symptoms other than the lump itself. Men generally feel well, and general symptoms appear only when the cancer has spread.
5.1 Symptoms in the breast and chest
- A painless lump or thickening under the nipple or in the chest, by far the most common first symptom
- A nipple that turns inwards
- Discharge from one nipple, especially if bloody
- Itching, redness, scaling or crusting of the nipple or areola
- Dimpling, puckering, redness or a sore on the skin of the chest
- Swelling or a change in the shape of one side of the chest
5.2 Symptoms from the lymph nodes
- A lump or swelling in the armpit
- Less often, a lump above the collarbone
5.3 Symptoms of advanced disease
If the cancer has spread to other organs, symptoms depend on where it has gone:
| Site of spread | Possible symptoms |
|---|---|
| Bones | Persistent back, hip or rib pain; fracture after minor injury. |
| Lungs | Cough or breathlessness. |
| Liver | Pain under the right ribs, jaundice, swollen abdomen. |
| Brain | Headaches, seizures, weakness, confusion. |
| General | Tiredness, poor appetite, weight loss. |
5.4 When to see a doctor
Many men wait months before seeing a doctor, out of embarrassment or because they do not know men can get breast cancer. A man should seek medical advice promptly if he notices:
- any new lump in the chest or armpit that does not go away
- a nipple that has recently turned inwards
- discharge from one nipple, especially blood
- a sore, rash or crusting on the nipple or chest skin that does not heal
Most of these changes turn out to be harmless, usually gynaecomastia. But only an examination can make that distinction, and finding cancer early makes treatment simpler and more successful.
6. Diagnosis
Diagnosis follows the same “triple assessment” used in women: clinical examination, imaging and biopsy.
6.1 Clinical examination
The doctor examines both sides of the chest, the nipples and the skin, and checks the lymph nodes in the armpits and above the collarbones. They will also ask about medicines, liver disease, alcohol use and family history of cancer.
6.2 Imaging
- Mammography: For men aged 25 or older, or when the examination is clearly suspicious, a diagnostic mammogram is the first imaging test. It works well in men and can show a mass, calcifications and the typical pattern of gynaecomastia.
- Ultrasound: Used to look more closely at a lump or the armpit nodes, and to guide a needle biopsy. In men under 25, in whom cancer is very unlikely, ultrasound is usually done first.
- MRI: Not part of the routine work-up but may help in selected cases.
6.3 Biopsy
A core needle biopsy, usually guided by ultrasound, is the standard way to confirm the diagnosis. A hollow needle removes thin cylinders of tissue for examination under the microscope. If armpit nodes look abnormal, they can be sampled too.
6.4 What the pathology report shows
| Report item | What it means in men |
|---|---|
| Type | Mostly invasive ductal carcinoma (about 85%); lobular and papillary types are uncommon; some have DCIS only. |
| Grade | 1 (slow) to 3 (fast); most are grade 2. |
| Hormone receptors | Almost always positive: 99% ER-positive, about 82% PR-positive (EORTC study). |
| HER2 | Positive in about 9%, fewer than in women. |
| Triple-negative | Very rare (0.3%). |
| Ki-67 | How fast the cells are dividing. |
7. Staging
Male breast cancer is staged in exactly the same way as breast cancer in women, using the AJCC TNM system (8th edition):
- T (tumour): Size of the tumour and whether it has grown into the skin or chest wall
- N (nodes): Spread to lymph nodes in the armpit, above the collarbone or behind the breastbone
- M (metastasis): Spread to distant organs
The AJCC system also produces a prognostic stage, which takes into account the grade, hormone receptor and HER2 status in addition to the anatomical extent.
| Stage | Simplified meaning |
|---|---|
| 0 | DCIS: cancer cells only inside the ducts |
| I | Small tumour (up to 2 cm), no or only microscopic node spread |
| II | Larger tumour and/or spread to a few armpit nodes |
| III | Locally advanced: large tumour, growth into skin or chest wall, or extensive node spread |
| IV | Spread to distant organs such as bone, lung, liver or brain |
Because the male breast is small, even a modest tumour can reach the skin or the chest muscle, which places it in a higher T category.
For small, early cancers without symptoms, no further scans are usually needed. For larger tumours, node-positive disease or symptoms suggesting spread, a CT scan of the chest and abdomen and a bone scan, or a PET-CT scan, are used to look for metastases.
8. Treatment
There are no large randomised trials in men because the disease is rare. Treatment therefore follows the principles used for women, adapted where men differ. The ASCO guideline on male breast cancer, published in 2020, summarises current recommendations. Treatment is planned by a multidisciplinary team.
8.1 Surgery
- Mastectomy: Removal of the breast tissue, including the nipple and areola, is the most common operation in men. In the EORTC international study, only 4% of men had breast-conserving surgery.
- Breast-conserving surgery (lumpectomy): Removing only the tumour with a margin of healthy tissue is possible for some men, if the usual criteria are met. It must be followed by radiotherapy.
- Sentinel lymph node biopsy: If the armpit nodes seem normal, the surgeon removes the first one to three “sentinel” nodes to check for spread. This is the standard approach in men, as in women.
- Axillary lymph node dissection: Removal of more armpit nodes. It is used when nodes are clearly involved, and carries a higher risk of arm swelling (lymphoedema) and shoulder stiffness.
8.2 Radiotherapy
- After lumpectomy: Radiotherapy to the remaining breast tissue is standard.
- After mastectomy: Recommended when the risk of the cancer returning in the chest wall or nodes is high, for example with several involved lymph nodes, a large tumour or a tumour growing into the skin or muscle.
- Palliative radiotherapy: Relieves pain or other symptoms from metastases, for example in bone or brain.
8.3 Hormone (endocrine) therapy
Hormone therapy is the backbone of treatment for the large majority of men, whose cancers are hormone receptor positive.
- Tamoxifen: Blocks the oestrogen receptor on cancer cells. ASCO recommends tamoxifen as the standard adjuvant (post-surgery) hormone therapy for men, initially for 5 years. Men at high risk of recurrence who tolerate it well may be offered another 5 years, for 10 in total.
- Side effects of tamoxifen in men: Hot flushes, reduced sex drive, erectile problems, weight gain, mood changes and a small risk of blood clots. These side effects lead many men to stop early, so they should be discussed openly with the care team.
- Aromatase inhibitors (anastrozole, letrozole, exemestane): These lower oestrogen production in women after menopause. In men, they should not be used on their own, because the testes keep producing hormones that are converted to oestrogen. A retrospective study of 257 men found higher mortality with an aromatase inhibitor alone than with tamoxifen. When tamoxifen cannot be used, an aromatase inhibitor is combined with a GnRH agonist or antagonist (such as leuprorelin or goserelin), which switches off testicular hormone production.
- Fulvestrant: An injectable drug that blocks and breaks down the oestrogen receptor, used for advanced disease.
8.4 Chemotherapy
Chemotherapy is used on the same basis as in women: for tumours with a higher risk of recurrence, such as node-positive, high-grade, HER2-positive or triple-negative cancers.
Common regimens include combinations of an anthracycline (doxorubicin or epirubicin), cyclophosphamide and a taxane (paclitaxel or docetaxel), or docetaxel with cyclophosphamide. For hormone receptor positive tumours, genomic tests on the tumour tissue can help decide whether chemotherapy is likely to be of benefit.
Chemotherapy can also be given before surgery (neoadjuvant) to shrink large or locally advanced tumours.
8.5 HER2-targeted therapy
For HER2-positive cancers, trastuzumab, often combined with pertuzumab, is given together with chemotherapy and then continued for about a year. Other HER2-directed drugs, such as trastuzumab emtansine, trastuzumab deruxtecan and tucatinib, are used in specific early or advanced settings.
8.6 Treatment of advanced (metastatic) disease
The aim is to control the cancer, relieve symptoms and keep a good quality of life for as long as possible.
| Treatment | When used | Notes |
|---|---|---|
| Hormone therapy | First choice for hormone receptor-positive advanced disease (ASCO), unless disease is rapidly progressing or threatens organs. | An aromatase inhibitor is given with a GnRH agonist in men. |
| CDK4/6 inhibitors | Palbociclib, ribociclib, abemaciclib with hormone therapy. | Used as in women; FDA extended palbociclib to men in April 2019. |
| PARP inhibitors | Olaparib or talazoparib. | Inherited BRCA1/2 variant and HER2-negative disease. |
| Other targeted drugs and ADCs | According to tumour markers. | Same indications as in women. |
| Bone-strengthening drugs | Zoledronic acid or denosumab. | Prevent fractures from bone metastases. |
9. Prognosis
The outlook depends mainly on the stage at diagnosis. The ACS, using SEER data for men diagnosed between 2015 and 2021, reports the following 5-year relative survival rates:
| SEER stage | 5-year relative survival |
|---|---|
| Localised (confined to the breast) | 97% |
| Regional (spread to nearby tissues or lymph nodes) | 86% |
| Distant (spread to distant organs) | 31% |
| All stages combined | 84% |
These figures are averages based on men treated several years ago. They cannot predict what will happen to an individual, and men diagnosed today may do better.
Factors that affect outlook
| Factor | Effect on outlook |
|---|---|
| Tumour size and lymph nodes | Most important; more nodes means higher recurrence risk. |
| Hormone receptor status | Strong positivity is linked to better survival. |
| Grade and HER2 | Guide treatment choices. |
| Age and health | Many men are older with other illnesses. |
| Finishing treatment | Stopping tamoxifen early raises recurrence risk. |
Men compared with women
Overall, survival after breast cancer is somewhat lower in men than in women. Part of the gap is explained by older age, later stage at diagnosis and differences in treatment.
A large US study of more than 16,000 men published in 2019 found that men had higher mortality than women at all stages. The difference remained even after adjusting for clinical features, treatment and access to care. Lower adherence to hormone therapy and biological differences may play a role.
10. Prevention and Early Detection
There is no routine breast screening for men in the general population. The most useful measures are:
- Awareness: Knowing that men can get breast cancer, and getting any new chest lump or nipple change checked promptly.
- Genetic testing for families: If a man has breast cancer or a family member carries a BRCA variant, relatives can be offered genetic counselling.
- Men with a BRCA variant: These men are usually advised to be breast-aware and to have regular clinical breast examinations. They are also advised to follow prostate cancer screening recommendations for carriers.
- General health: Keeping a healthy weight, limiting alcohol and protecting the liver reduce the hormonal changes that raise risk.
11. Living with Male Breast Cancer
11.1 Follow-up
After treatment, men have regular check-ups with their oncology team, usually every few months at first and then once or twice a year. The ASCO guideline recommends:
- an annual mammogram of the treated side for men who had a lumpectomy
- an annual mammogram of the other side may be offered to men with an inherited gene variant
- no routine breast MRI
11.2 Managing side effects and late effects
- Lymphoedema: Swelling of the arm after armpit surgery or radiotherapy. Early physiotherapy, skin care and compression garments help.
- Hormone therapy side effects: Hot flushes, erectile problems and mood changes can often be eased. Men should raise them rather than stopping treatment on their own.
- Bone health: An aromatase inhibitor combined with a GnRH agonist lowers testosterone and can thin the bones. Bone density checks, calcium, vitamin D and exercise are advised, and bone-protecting drugs may be needed.
- Heart health: Anthracycline chemotherapy and trastuzumab can affect the heart, so heart function is monitored.
11.3 Emotional and social aspects
Many men describe feeling isolated or embarrassed by having a “woman’s disease”. Information leaflets, waiting rooms and support groups are often designed for women.
Talking openly with the care team, seeing a psycho-oncologist or counsellor and connecting with other men through patient organisations for men with breast cancer can make a real difference. The loss of the nipple and the scar can affect body image, for example when swimming or changing in public, and nipple reconstruction or tattooing is possible.
11.4 Family
Because a BRCA2 or other inherited variant may be found, a diagnosis in a man can have consequences for his daughters, sons, sisters and brothers. Genetic counselling helps the family understand their own risks and options.
12. Frequently Asked Questions
| Question | Answer |
|---|---|
| Can men really get breast cancer? | Yes. Men have breast tissue behind the nipple, and it can develop cancer. In the US, about 2,670 men are expected to be diagnosed in 2026. |
| Is a lump under my nipple likely to be cancer? | Usually not. Most lumps in men are gynaecomastia, a benign enlargement of breast tissue. But a hard, painless lump on one side, especially with nipple changes, should be checked without delay. |
| Is male breast cancer treated differently from breast cancer in women? | Mostly the same principles apply. The main differences are that mastectomy is more common and that tamoxifen is the preferred hormone treatment, because an aromatase inhibitor alone does not work well in men. |
| Should I have genetic testing? | Genetic counselling and testing are recommended for every man diagnosed with breast cancer. |
| Will hormone therapy affect my sex life? | Tamoxifen can reduce sex drive and cause erectile problems in some men. Tell your care team, as these effects can often be managed. |
| Is the outlook worse than for women? | Survival is very good when the cancer is found early. On average, survival is somewhat lower in men, partly because they are older and diagnosed later. |
13. Conclusion
Male breast cancer is rare, but it is real, and lack of awareness is one of its biggest dangers. The typical sign is a hard, painless lump under one nipple, sometimes with a retracted nipple, bloody discharge or skin changes.
Almost all these cancers are driven by hormones, and inherited BRCA2 variants play an important role. Treatment usually combines surgery with tamoxifen, plus radiotherapy, chemotherapy or targeted drugs when needed.
Found early, male breast cancer has an excellent outlook. Knowing the signs and getting any change in the chest checked promptly are the most important steps a man can take.
Resources
- Giordano, S.H. (2018) ‘Breast cancer in men’, New England Journal of Medicine, 378(24), pp. 2311-2320.
- Hassett, M.J. et al. (2020) ‘Management of male breast cancer: ASCO guideline’, Journal of Clinical Oncology, 38(16), pp. 1849-1863.
- Cardoso, F. et al. (2018) ‘Characterization of male breast cancer: results of the EORTC 10085/TBCRC/BIG/NABCG International Male Breast Cancer Program’, Annals of Oncology, 29(2), pp. 405-417.
- Tai, Y.C. et al. (2007) ‘Breast cancer risk among male BRCA1 and BRCA2 mutation carriers’, Journal of the National Cancer Institute, 99(23), pp. 1811-1814.
- Swerdlow, A.J. et al. (2005) ‘Cancer incidence and mortality in men with Klinefelter syndrome: a cohort study’, Journal of the National Cancer Institute, 97(16), pp. 1204-1210.
- Eggemann, H. et al. (2013) ‘Adjuvant therapy with tamoxifen compared to aromatase inhibitors for 257 male breast cancer patients’, Breast Cancer Research and Treatment, 137(2), pp. 465-470.
- Wang, F. et al. (2019) ‘Overall mortality after diagnosis of breast cancer in men vs women’, JAMA Oncology, 5(11), pp. 1589-1596.
- National Cancer Institute (2026) Male Breast Cancer Treatment (PDQ®) – Health Professional Version. Available at: https://www.cancer.gov/types/breast/hp/male-breast-treatment-pdq (Accessed: October 2026).
- American Cancer Society (2026) Key Statistics for Breast Cancer in Men. Available at: https://www.cancer.org/cancer/types/breast-cancer-in-men/about/key-statistics.html (Accessed: October 2026).
- American Cancer Society (2026) Breast Cancer Survival Rates in Men. Available at: https://www.cancer.org/cancer/types/breast-cancer-in-men/detection-diagnosis-staging/survival-rates.html (Accessed: October 2026).
Prepared by the editorial team, October 2026.